19 July 2018 in American Journal of Neuroradiology
BACKGROUND AND PURPOSE: Recent studies have suggested that wall enhancement of unruptured intracranial aneurysms in high-resolution MR imaging might serve as an imaging biomarker for higher risk of rupture. Histologic studies have revealed a possible association among inflammatory processes, degeneration, and destabilization of the aneurysm wall preceding rupture. Understanding the histologic condition underlying aneurysm wall enhancement could be an important step toward assessing the value of this method for risk stratification. We present our observations of aneurysm wall enhancement in MR vessel wall imaging and underlying histologic changes. MATERIALS AND METHODS: We reviewed records of patients with an unruptured middle cerebral artery aneurysm who underwent MR vessel wall imaging before aneurysm clipping. Contrast enhancement of the aneurysm wall was dichotomized into either none/faint or strong. Histologic analysis included myeloperoxidase stain for detection of inflammatory cell invasion and CD34 stain for assessment of neovascularization and vasa vasorum. RESULTS: Thirteen aneurysms were included. Five aneurysms showed strong wall enhancement. Among these, myeloperoxidase staining revealed inflammatory cell infiltration in 4. Three showed neovascularization. In 2 aneurysms, vasa vasorum were present. Seven aneurysms did not show wall enhancement; 1 had only mild enhancement. None of these bore evidence of inflammatory cell invasion or neovascularization, and they all lacked vasa vasorum. CONCLUSIONS: Wall enhancement in MR vessel wall imaging is associated with inflammatory cell invasion, neovascularization, and the presence of vasa vasorum. Enhancement does not occur when histologic signs of inflammation are absent. Our results support the hypothesis that MR vessel wall imaging could provide valuable information for risk stratification.
17 July 2020 in Neuroradiology
Purpose: Circumferential enhancement on MR vessel wall imaging has been proposed as a biomarker of a higher risk of rupture in intracranial aneurysms. Focal enhancement is frequently encountered in unruptured aneurysms, but its implication for risk stratification and patient management remains unclear. This study investigates the association of focal wall enhancement with hemodynamic and morphological risk factors and histologic markers of wall inflammation and degeneration. Methods: Patients with an unruptured middle cerebral artery aneurysm who underwent 3D rotational angiography and 3T MR vessel wall imaging showing focal wall enhancement were included. Hemodynamic parameters were calculated based on flow simulations and compared between enhanced regions and the entire aneurysm surface. Morphological parameters were semiautomatically extracted and quantitatively associated with wall enhancement. Histological analysis included detection of vasa vasorum, CD34, and myeloperoxidase staining in a subset of patients. Results: Twenty-two aneurysms were analyzed. Enhanced regions were significantly associated with lower AWSS, lower maxOSI, and increased LSA. In multivariate analysis, higher ellipticity index was an independent predictor of wall enhancement. Histologic signs of inflammation and degeneration and higher PHASES score were significantly associated with focal enhancement. Conclusion: Focal wall enhancement is colocalized with hemodynamic factors that have been related to a higher rupture risk. It is correlated with morphological factors linked to rupture risk, higher PHASES score, and histologic markers of wall destabilization. The results support the hypothesis that focal enhancement could serve as a surrogate marker for aneurysm instability.
21 November 2019 in Clinical Neuroradiology
1 September 2014 in Neuro-Oncology
OBJECTIVE: Malignant gliomas are the most frequent primary tumours of the brain with poor clinical prognosis. Infiltrating peripheral macrophages and resident microglia that constitute the dominant tumour-[[Unsupported Character - Codename ]]-infiltrating cells in glioblastoma are induced by the glioma cells to become immunosuppressive and tumour supportive. Glioma-[[Unsupported Character - Codename ]]-initiating cells (GIC) could potentially promote this pro-[[Unsupported Character - Codename ]]-tumorigenic phenotype. Exploring the interaction between GIC and glioma associated microglia/macrophages (GAM) may offer us an opportunity to further understand the cellular and molecular features of the GIC niche. We here investigate the potential of GIC versus bulk cells to induce a pro-[[Unsupported Character - Codename ]]- tumorigenic microglial cytokine profile. METHODS: In the present study we stimulated primary cultured microglia with glioma conditioned medium (GCM) from GICs enriched or depleted GL261 cells and cytokine levels were determined by FlowCytomix. RESULTS: An almost 4-[[Unsupported Character - Codename ]]-fold upregulation in microglial IL-[[Unsupported Character - Codename ]]-6 secretion was observed using GCM from GICs while the secretion was unchanged with GCM from GICs depleted GL261 cells. Since Toll-[[Unsupported Character - Codename ]]-like receptors are pattern recognition receptors that are responsible for pro-[[Unsupported Character - Codename ]]-inflammatory cytokines release, we screened through all the TLRs and identified TLR4 as the main TLR controlling microglial IL-[[Unsupported Character - Codename ]]-6 secretion. IL-[[Unsupported Character - Codename ]]-6R and gp130 are highly expressed in GICs but not in microglial cells. The implantation of GL261-[[Unsupported Character - Codename ]]-EGFP cells into IL-[[Unsupported Character - Codename ]]-6 -[[Unsupported Character - Codename ]]-/-[[Unsupported Character - Codename ]]- mice resulted in significantly smaller tumours as compared to wild-[[Unsupported Character - Codename ]]- type control mice. IL-[[Unsupported Character - Codename ]]-6 and IL-[[Unsupported Character - Codename ]]-6R are also expressed in human gliomas (which contain up to 30% microglia/macrophages) and inversely correlates with patient survival. CONCLUSIONS: Our results show that GICs, but not the bulk glioma cells initiate microglial IL-[[Unsupported Character - Codename ]]-6 secretion. IL-[[Unsupported Character - Codename ]]-6 in turn promotes glioma cell growth and invasion.
1 November 2022 in Neuro-Oncology
Transcriptomic screens of brain tumor (glioblastoma; GBM) parenchymal cells indicated tumor supporting traits of the GBM microenvironment, but largely excluded mitochondrially enriched gene-sets. Here, we show that a mitochondrial transcript of GBM parenchymal cells contributes to therapy resistance. We inspected the non-coding transcriptome of human GBM associated myeloid cells (GAM) and observed an upregulation of the mitochondrial ribosomal subunit MT-RNR2, which contains an open reading frame for the signaling peptide humanin. Immunohistology disclosed that humanin was preponderant in GAM. In vitro assays with a range of human stem-like GBM cells (GSCs) revealed that nanomolar concentrations of humanin can drive tumor cell expansion and chemoresistance to temozolomide. A series of genetic, pharmacological and Western blotting experiments showed that extracellular humanin increased GSC viability via stimulation of the GP130/IL6ST receptor and MAPK (Erk) activation. Humanin responsiveness was subject to inter-individual heterogeneity and predominated in GSC with high expression levels of the IL6ST subunit. Mechanistically, humanin promoted the ATR-dependent DNA-repair machinery in GSCs via induction of the DNA-clamp component HUS1. A slice culture model containing human microglia and GSCs confirmed these observations. Humanin is absent from the mouse brain. Exogenous delivery of humanin into orthotopic GBM mouse models or over-expression specifically of a secreted humanin variant recapitulated the in vitro findings. Blockade of the trimeric interleukin receptor with the brain permeant, FDA-approved drug bazedoxifene blocked humanin-mediated chemoresistance in vitro and in vivo. Overall, we identified a clinically applicable compound together with a predictive marker to prevent chemoresistance in a human-specific GBM model.